Journal Club: pharmaceutical

This site is a B2B information site for professional use - clinical diagnostics products listed are for Research Use Only unless otherwise stated.

MAGneat Myzol for TRIzol RNA Extraction Kit

advertisement

Lonza QC ecosystem for a sustainable future

advertisement

bioMerieux Biofire Spotfire Mycoplasma testing

advertisement

Journal club brings you key findings from selected peer reviewed published papers

advertisement

Journal Club: pharmaceutical

Join Our Journal Club - Understand Emerging Trends and Breakthrough Discoveries

View by sector:

Go

Journal Club - 22 Feb to 2 March 2026

Journal Club

Air Sampling Aspergillus Identification

02 Mar 2026

Latest from our Journal Club: Measles cases are resurging globally, FDA reports the most common microorganisms in pharmaceuticals, and DNA metabarcoding of air samples from waste sorting plants enhances microbial risk assessment.
Clinical & Veterinary Other Pharmaceutical

Review of FDA Enforcement: Microbial Contaminants in Sterile and Non-sterile Pharmaceuticals

Review of FDA enforcement reports demonstrates patterns of microbial contamination

Aspergillus Burkholderia cepacia complex (BCC)Identification

25 Feb 2026 Lora Benoit Ph.D

FDA enforcement reports (2004–2025) were analyzed to define microbial contamination events driving recalls of drugs. The most common microorganisms detected were Aspergillus penicilloides, followed by Burkholderia cepacia complex (BCC).
Pharmaceutical

Journal Club - 1 Feb to 13 Feb 2026

Journal Club Highlights

Cleanroom Hospital Acquired Infection (HAI)Rhinovirus

17 Feb 2026 Lora Benoit Ph.D

Latest from our Journal Club covering: targeted, risk-based sampling to maintain cleanroom compliance, importance of antimicrobial therapy and robust infection control in postoperative care, plus how the severity of rhinovirus disease may be due to inadequate early antiviral signalling.
Clinical & Veterinary Pharmaceutical

Why Some Colds Hit Harder: Rhinovirus vs Innate Immunity

Innate immune functions dictate the severity of cold symptoms

Rhinovirus

10 Feb 2026 Lora Benoit Ph.D

Rhinovirus infection can trigger robust interferon responses at the level of the epithelium, which are protective; in their absence, inflammatory signaling arises which can lead to severe cold symptoms.
Clinical & Veterinary Pharmaceutical

Risk-Based Monitoring of a Class D Cleanroom

Environmental monitoring of Class D cleanrooms

Cleanroom Environmental Monitoring

10 Feb 2026 Lora Benoit Ph.D

Environmental monitoring of a Class D pharmaceutical facility highlights the value of targeted, risk-based sampling to maintain cleanroom compliance.
Pharmaceutical

Journal Club - Week 2: 7 Jan to 14 Jan 2026

rapidmicrobiology Journal Club

Avian Influenza Bacillus cereus Streptococcus pneumoniae

14 Jan 2026

At a glance summaries of studies on rapid sterility testing for ATMPs, pathogenic Avian flu testing, incidence of B. cereus in infant formula, accurate serotyping of S. pneumoniae.
Food & Beverage Clinical & Veterinary Pharmaceutical

2-Day Sterility Testing for Cell-Based Therapeutics

Rapid and reliable sterility testing of ATMP

ATMP - Advanced Therapeutic Medicinal Products Cell and Gene Therapies Sterility Testing

02 Jan 2026 Lora Benoit Ph.D

Using an automated blood culture system, researchers demonstrated that mesenchymal stem cell (MSC) therapeutic preparations can be reliably screened for microbial contamination within 48 hr, supporting substantially faster product release compared with conventional 14-day sterility testing.
Pharmaceutical

Everything You Need to Know About Equipment Validation for Sterility Testing

Sterility Testing of Cell and Gene Therapy Products

ATMP - Advanced Therapeutic Medicinal Products Cell and Gene Therapies Journal Club

14 Oct 2025 Lora Benoit Ph.D

As novel biologics and cell therapies advance, sterility testing is becoming increasingly complex and subject to cGMP scrutiny. Gebo et al. outline how clinical microbiology labs - traditionally CLIA/CAP-regulated - can align with FDA, USP, and ISO expectations.
Clinical & Veterinary Pharmaceutical

Reducing Uncertainty in Bioburden Testing: A Statistical Framework for Pharma QA

Reducing Uncertainty in Bioburden Testing

Bioburden Journal Club

08 Oct 2025 Lora Benoit Ph.D

In biopharmaceutical manufacturing, variability in bioburden testing poses significant challenges for maintaining product quality. Here, a statistical framework designed to improve the interpretation of bioburden test outcomes - enhance regulatory compliance and increase consistency.
Pharmaceutical

1
2
3
4
›

MAGneat Myzol for TRIzol RNA Extraction Kit

advertisement

Lonza QC ecosystem for a sustainable future

advertisement

bioMerieux Biofire Spotfire Mycoplasma testing

advertisement

Journal club brings you key findings from selected peer reviewed published papers

advertisement

© 2001 - 2026 Rapid Test Methods Ltd. All rights reserved.